Clinical Trial Update: Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Withdrawn Phase 2 trial evaluating second-line docetaxel plus ASA-404 for advanced urothelial carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• ASA-404 (vadimezan)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Hoosier Cancer Research Network | Conditions: Urothelial Carcinoma | Phase 2 | Status: WITHDRAWN